A Study to Evaluate the Efficacy and Safety of AD-224

ConditionHypertension,Essential

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age19+

SponsorAddpharma Inc.

About this trial

The purpose of this study is to evaluate the efficacy and safety of AD-224

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent

Patients with Essential Hypertension

Other inclusions applied

Disqualifiers

Patient with Secondary Hypertension

Other exclusions applied

Trial design

Design model

Parallel

Treatments tested in this trial

AD-224A
Drug
PO, Once daily, 8weeks
AD-224B
Drug
PO, Once daily, 8weeks
AD-224C
Drug
PO, Once daily, 8weeks
Placebo of AD-224A
Drug
PO, Once daily, 8weeks
Placebo of AD-224B
Drug
PO, Once daily, 8weeks
Placebo of AD-224C
Drug
PO, Once daily, 8weeks

Treatment groups

252 Participants

are divided into 3 treatment groups

Group A: AD-224AExperimental treatment 3 interventions

Group B: AD-224BExperimental treatment 3 interventions

Group C: AD-224CActive comparator 3 interventions

Trial outcomes

Primary outcomes

Change rate of MSSBP

Change from baseline in mean sitting systolic blood pressure

Time frame

Baseline, Week 8

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

Apply now